Claims for Patent: 12,257,242

Summary for Patent: 12,257,242

Title:	Inhibition of crystal growth of roflumilast
Abstract:	Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
Inventor(s):	David W. Osborne
Assignee:	Arcutis Biotherapeutics Inc
Application Number:	US18/465,446
Patent Claims:	1. A topical pharmaceutical composition comprising roflumilast in an amount of 0.05%-1% w/w, hexylene glycol, and water, wherein the hexylene glycol is in an amount sufficient to inhibit crystal growth of roflumilast in the composition for at least six weeks of storage at 15° C.-26° C., wherein the composition is in the form of a cream or foam. 2. The composition of claim 1, wherein the hexylene glycol inhibits growth of any precipitated roflumilast particles for at least six weeks of storage at 15° C.-26° C. 3. The composition of claim 2, wherein the hexylene glycol is in an amount sufficient to inhibit growth of the precipitated roflumilast particles over a shelf life of the composition. 4. The composition of claim 1, wherein the hexylene glycol inhibits a change in particle size distribution for at least six weeks of storage at 15° C.-26° C. 5. The composition of claim 4, wherein the hexylene glycol inhibits a change in particle size distribution over a shelf life of the composition. 6. The composition of claim 1, wherein said composition is a cream. 7. The composition of claim 1, wherein said roflumilast is in an amount of 0.1-0.5% w/w. 8. The composition of claim 1, wherein said composition further comprises diethylene glycol monoethyl ether. 9. The composition of claim 8, wherein said diethylene glycol monoethyl ether is in an amount of 25% w/w. 10. The composition of claim 1, wherein said composition further comprises one or more emulsifiers. 11. The composition of claim 10, wherein said emulsifier is in an amount of 10% w/w. 12. The composition of claim 10, wherein said emulsifier is a blend comprising cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate. 13. The composition of claim 1, wherein the composition further comprises diethylene glycol monoethyl ether, an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate, isopropyl palmitate and white petrolatum. 14. The composition of claim 13, wherein said diethylene glycol monoethyl ether is in an amount of 25% w/w, said emulsifier blend is in an amount of 10% w/w, said isopropyl palmitate is in an amount of 5% w/w, and said white petrolatum is in an amount of 10% w/w. 15. A topical pharmaceutical composition comprising roflumilast in an amount of 0.05%-1% w/w, hexylene glycol, water, and one or more pharmaceutically acceptable excipients, wherein the hexylene glycol is in an amount sufficient to inhibit crystal growth of the roflumilast, and wherein any precipitated roflumilast returns to a dissolved state when the formulation returns to 15° C.-26° C. following exposure to a temperature below 15° C. 16. The composition of claim 15, wherein any precipitated roflumilast returns to a dissolved state when the formulation returns to 15° C.-26° C. following exposure to a temperature of 0° C. 17. The composition of claim 16, wherein the composition further comprises an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate. 18. The composition of claim 16, wherein the composition further comprises diethylene glycol monoethyl ether. 19. The composition of claim 16, wherein the composition further comprises diethylene glycol monoethyl ether, an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate, isopropyl palmitate and white petrolatum, and wherein the composition is in the form of a foam or cream. 20. The composition of claim 19, wherein said diethylene glycol monoethyl ether is in an amount of 25% w/w, said emulsifier blend is in an amount of 10% w/w, said isopropyl palmitate is in an amount of 5% w/w, and said white petrolatum is in an amount of 10% w/w. 21. The composition of claim 1, wherein the roflumilast particle size does not grow more than 100%. 22. The composition of claim 1, wherein the roflumilast particles are less than 100 microns in length. 23. The composition of claim 16, wherein said water is in an amount of about 47.25% w/w. 24. The composition of claim 3, wherein said water is in an amount of about 47.25% w/w. 25. The composition of claim 5, wherein said water is in an amount of about 47.25% w/w.